Edi Therapeutics LLC
Publicly observedRochester, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Rochester | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Edi Therapeutics LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | P6VEXK48QFJ8 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Sept 2026Publicly observed
NIH SBIR/STTR award: Development of EDI-239382, a novel IRAK4 inhibitor to control inflammation driven metastasis, immune dysfunction and chemoresistance niche in ovarian tumors.
USD 377,537.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jun 2026Publicly observed
NIH SBIR/STTR award: Chimectin as a novel wound biologic for xylazine-induced tissue injury
USD 274,219.00 · National Institute on Drug Abuse · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.